Interventions-Twice daily lipid lowering treatment was given, with the fibrate administered in the morning (either bezafibrate 400 mg (n = 101) or fenofibrate 200 mg (n = 1)) and the statin in the evening (either simvastatin 10 mg (n = 23), 20 mg (n = 72), or 40 mg (n = 2) or pravastatin 10 mg (n = 1) or 20 mg (n = 4)). Treatment continued for 1 (n = 9), 2 (n = 58), or 3 (n = 35) years. Main outcome measures-Selected laboratory variables (total cholesterol concentration and liver (aspartate transaminase (AST)) and muscle enzyme (creatine kinase (CK)) activities) and documented symptomatology. Results-A mean (SD) total cholesterol concentration of 5 2 (0.8) mmolIl was achieved after combined treatment for 1 year which was maintained at annual follow up. Over a maximum 3 year follow up no patient reported myalgic symptoms and none had a measured CK activity > 10 times above nomal. Four men on a simvastatinbezafibrate combination had a CK activity rise to less than three times normal. Fourteen patients with a negative history of alcohol excess (consumption < 21 units/week) had borderline raised AST values. Conclusions-Statin-fibrate combination treatment for up to 3 years in a cohort of patients with coronary artery disease was not associated with serious disturbances in biochemical markers of muscle or liver function. (Br Heart J 1995;74:14-17) 
patients with documented coronary artery disease and who had been treated with a statin-fibrate combination for over 1 year. Coronary artery disease was confirmed by angiography in 93 patients and by a positive (Bruce protocol) exercise test in the remainder. Fifty eight patients had a history of previous coronary bypass graft surgery. Interventions-Twice daily lipid lowering treatment was given, with the fibrate administered in the morning (either bezafibrate 400 mg (n = 101) or fenofibrate 200 mg (n = 1)) and the statin in the evening (either simvastatin 10 mg (n = 23), 20 mg (n = 72), or 40 mg (n = 2) or pravastatin 10 mg (n = 1) or 20 mg (n = 4)). Treatment continued for 1 (n = 9), 2 (n = 58), or 3 (n = 35) years. Main outcome measures-Selected laboratory variables (total cholesterol concentration and liver (aspartate transaminase (AST)) and muscle enzyme (creatine kinase (CK)) activities) and documented symptomatology. Results 0  175  53  3  63  M  2  6  73  73  4  70  M  3  12  314  68  5  60  M  3  20  59  52  6  77  M  3  20  93  58  7  57  M  3  0  97  46  8  73  M  1  10  263  48  9  59  M  3  12  196  45  10  69  F  1  0  72  53  11  55  F  2  10  24  165  12  61  M  2  10  235  44  13  43  M   2  21  243  43  14  62  M   2  0  233  60 NR, normal range.
Results
Of the cohort of 102 patients, safety data were collected prospectively over a 3 year treatment period in 35, over 2 years in 58 and over 1 year in nine. For the whole group, the pretreatment mean (SD) serum total cholesterol concentration of 7-4 (1 6) mmol/l was reduced to 5-2 (0 8) mmol/I after combination drug treatment for 1 year. This reduction in total cholesterol was maintained at the 2 and 3 year follow up. Over a maximum 3 year follow up no patient reported myalgic symptoms and none had increased plasma CK activity 10 times above normal. Four male patients treated with a simvastatin-bezafibrate combination had an increase in CK activity above the reference range ( 16 This finding has also been reported for lovastatin given with either nicotinic acid'0 or gemfibrozil.78 In most cases where there were clinical features of myositis or rhabdomyolysis, lovastatin had been the prescribed statin. By comparison, there are no cases using other statins and there has been only one report of an association with low dose simvastatin, with the adverse event occurring 3 months after the start of treatment. 7 The recent evidence that untreated hypercholesterolaemic patients may have increased muscle enzyme activities,'8 both before and after exercise (JWA Smit et al, 62nd European Atherosclerosis Society meeting, Jerusalem, Israel, 1993) highlights the difficulties in attributing a single causative role to statin or fibrate drugs (either singularly or in combination) in initiating the altered muscle biochemistry.
There have been reports of transient increases in serum liver transaminases with fibrate treatment'920 and up to three times normal values in about 1-5% of patients treated with statins.21 There are few data, however, on the numbers of patients withdrawn from such treatment because of this adverse effect. It is of interest in the present study in which both drug groups were used in combination that only one patient had an increase of three times the upper normal AST activity and the remaining patients had only borderline changes in AST values.
Cholesterol 2426 It is of interest that none of these studies documented any occurrence of myositis or myopathy.
While previous individual case reports have given concern about the concurrent use of a statin with a fibrate in particular gemfibrozil with lovastatin,478 this safety study involving patients with coronary artery disease has confirmed the findings of previous studies of statin-fibrate treatment which were of shorter duration and involved fewer numbers of patients. The combination was not only effective in achieving the desirable cholesterol concentration in a large number of patients at high risk of vascular disease, but was also associated with no serious disturbance in biochemical markers of muscle or liver function.
Our observations may reflect the particular selection of treated individuals who were regular clinic attendees, tablet compliant, avoided alcohol excess and who had not been a transplant recipient requiring cyclosporin or was in established renal failure. The use of fibrates-other than gemfibrozil-together with statins-other than lovastatin-as well as the intensive monitoring through regular clinic attendance with telephone back up, may have also accounted for the observed lack of any serious adverse event in this study.
Combination treatment of selected statin and fibrate drugs with appropriate monitoring may have a useful role in achieving desirable cholesterol concentrations, without hazard, in patients with documented coronary artery disease.
